与¹³¹I标记的单克隆抗体相比，¹⁸⁶Re标记的单克隆抗体局部区域放射免疫疗法治疗小鼠结肠癌小腹膜癌病

Locoreginal radioimmunotherapy with 186Re-labeled monoclonal antibody in treating small peritoneal carcinomatosis of colon cancer in mice in comparison with 131I-counterpart.

作者信息

Kinuya Seigo, Yokoyama Kunihiko, Izumo Mishiroku, Sorita Takami, Obata Takashi, Mori Hirofumi, Shiba Kazuhiro, Watanabe Naoto, Shuke Noriyuki, Michigishi Takatoshi, Tonami Norihisa

机构信息

Department of Biotracer Medicine, Kanazawa University Graduate School of Medical Sciences, 13-1 Takaramachi, Kanazawa, Ishikawa 920-8640, Japan.

出版信息

Cancer Lett. 2005 Feb 28;219(1):41-8. doi: 10.1016/j.canlet.2004.08.033.

DOI:10.1016/j.canlet.2004.08.033

PMID:15694663

Abstract

The efficacy of locoregional radioimmunotherapy (RIT) in treating peritoneal tumors of colon cancer of <2 mm in diameter was examined at maximum tolerated doses, focusing the comparison between 186Re and 131I labeled to an anti-colorectal cancer IgG1. Estimated radiation doses to tumors were considerably higher with 186Re-RIT than with 131I-RIT. The advantage of 186Re-RIT decreased with decreasing tumor size, but 186Re-RIT delivered 1.6-times higher radiation to tumors of 1 mm. Consequently, 186Re-RIT attained better survival of mice than 131I-RIT or chemotherapy with 5-fluorouracil did. Therefore, locoregional 186Re-RIT may be an option in an adjuvant setting of colon cancer with high risk of peritoneal dissemination.

摘要

在最大耐受剂量下，研究了局部区域放射免疫疗法（RIT）治疗直径小于2毫米的结肠癌腹膜肿瘤的疗效，重点比较了标记于抗结直肠癌IgG1的186Re和131I。与131I-RIT相比，186Re-RIT对肿瘤的估计辐射剂量要高得多。186Re-RIT的优势随着肿瘤尺寸的减小而降低，但186Re-RIT对1毫米肿瘤的辐射量要高1.6倍。因此，186Re-RIT使小鼠的生存期比131I-RIT或5-氟尿嘧啶化疗更好。所以，局部区域186Re-RIT可能是结肠癌腹膜播散高风险辅助治疗中的一种选择。